arabinofuranosylcytosine triphosphate has been researched along with dipyridamole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, TC | 1 |
| Horber, DH; Schott, H; Schwendener, RA | 1 |
2 other study(ies) available for arabinofuranosylcytosine triphosphate and dipyridamole
| Article | Year |
|---|---|
Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Dipyridamole; DNA Damage; Drug Synergism; Humans; Tumor Cells, Cultured | 1989 |
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Cell Differentiation; Cytarabine; Dipyridamole; DNA; Drug Carriers; Drug Interactions; Half-Life; Humans; Leukemia; Liposomes; Tumor Cells, Cultured | 1995 |